drugset / Trial / NCT00518622
Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the effectiveness, safety, and tolerability of MK7009 in patients infected with Hepatitis C
Timeline
- Start
- 2007-07
- Primary completion
- 2008-09
- Completion
- 2008-09
Outcome
Met primary endpoint
registry analysis (superiority or other test); 25 mg b.i.d. MK7009 vs Placebo; Mean Difference (Net) -2.01 (95% CI -2.87 to -1.14) NCT00518622 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vaniprevir | Small molecule | 25 mg | — |
| Subject | Vaniprevir | Small molecule | 75 mg | — |
| Subject | Vaniprevir | Small molecule | 125 mg | — |
| Subject | Vaniprevir | Small molecule | 250 mg | — |
| Subject | Vaniprevir | Small molecule | 500 mg | — |
| Subject | Vaniprevir | Small molecule | 600 mg | — |
| Subject | Vaniprevir | Small molecule | 700 mg | — |